middle.news
Lumos Diagnostics Advances FebriDx Study, Secures Key BARDA Milestone Payment
9:55am on Wednesday 18th of June, 2025 AEST
•
Healthcare
Read Story
Lumos Diagnostics Advances FebriDx Study, Secures Key BARDA Milestone Payment
9:55am on Wednesday 18th of June, 2025 AEST
Key Points
500 patients enrolled in FebriDx CLIA waiver clinical study
US$298,457 milestone payment received from BARDA
78 of 120 bacterial positive patients enrolled, with improved prevalence after enrichment
Study expected to complete by Q4 2025, FDA CLIA waiver application targeted for October 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics Holdings (ASX:LDX)
OPEN ARTICLE